Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparing ARomatase Inhibition when given with or without SaracaTinib as an Advanced breast CAncer Therapy (ARISTACAT): a randomised phase II study of aromatase inhibition with or without the src-inhibitor AZD0530 in post-menopausal women with advanced breast cancer

Next Previous
X
Search
Trial Profile

Comparing ARomatase Inhibition when given with or without SaracaTinib as an Advanced breast CAncer Therapy (ARISTACAT): a randomised phase II study of aromatase inhibition with or without the src-inhibitor AZD0530 in post-menopausal women with advanced breast cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Saracatinib (Primary) ; Anastrozole; Exemestane
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms ARISTACAT

    • Most Recent Events

    • 01 May 2023 Primary endpoint (Progression-free survival) has not been met, as per results published in the Breast Cancer Research and Treatment.
    • 01 May 2023 Results assessing the efficacy of saracatinib addition to aromatase inhibitors in patients with hormone receptor-positive metastatic breast cancer, published in the Breast Cancer Research and Treatment.
    • 14 Dec 2019 Results presented at the 42nd Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top